362 related articles for article (PubMed ID: 31664646)
1. CRISPR/Cas9-mediated gene correction in hemophilia B patient-derived iPSCs.
Morishige S; Mizuno S; Ozawa H; Nakamura T; Mazahery A; Nomura K; Seki R; Mouri F; Osaki K; Yamamura K; Okamura T; Nagafuji K
Int J Hematol; 2020 Feb; 111(2):225-233. PubMed ID: 31664646
[TBL] [Abstract][Full Text] [Related]
2. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
[TBL] [Abstract][Full Text] [Related]
3. Successful correction of factor V deficiency of patient-derived iPSCs by CRISPR/Cas9-mediated gene editing.
Nakamura T; Morishige S; Ozawa H; Kuboyama K; Yamasaki Y; Oya S; Yamaguchi M; Aoyama K; Seki R; Mouri F; Osaki K; Okamura T; Mizuno S; Nagafuji K
Haemophilia; 2020 Sep; 26(5):826-833. PubMed ID: 32700411
[TBL] [Abstract][Full Text] [Related]
4. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system.
Itoh M; Kawagoe S; Tamai K; Nakagawa H; Asahina A; Okano HJ
J Dermatol Sci; 2020 Jun; 98(3):163-172. PubMed ID: 32376152
[TBL] [Abstract][Full Text] [Related]
5. Designer nuclease-mediated gene correction via homology-directed repair in an in vitro model of canine hemophilia B.
Bergmann T; Ehrke-Schulz E; Gao J; Schiwon M; Schildgen V; David S; Schildgen O; Ehrhardt A
J Gene Med; 2018 May; 20(5):e3020. PubMed ID: 29608237
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-Mediated In Situ Introduction or Integration of
Tang Q; Hu Z; Zhao J; Zhou T; Tang S; Wang P; Xiao R; Chen Y; Wu L; Zhou M; Liang D
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240366
[TBL] [Abstract][Full Text] [Related]
7. Genetic Correction and Hepatic Differentiation of Hemophilia B-specific Human Induced Pluripotent Stem Cells.
He Q; Wang HH; Cheng T; Yuan WP; Ma YP; Jiang YP; Ren ZH
Chin Med Sci J; 2017 Sep; 32(3):135-144. PubMed ID: 28956740
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9-mediated somatic and germline gene correction to restore hemostasis in hemophilia B mice.
Huai C; Jia C; Sun R; Xu P; Min T; Wang Q; Zheng C; Chen H; Lu D
Hum Genet; 2017 Jul; 136(7):875-883. PubMed ID: 28508290
[TBL] [Abstract][Full Text] [Related]
9. Paired CRISPR/Cas9 Nickases Mediate Efficient Site-Specific Integration of
Wang Y; Zhao J; Duan N; Liu W; Zhang Y; Zhou M; Hu Z; Feng M; Liu X; Wu L; Li Z; Liang D
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30301136
[TBL] [Abstract][Full Text] [Related]
10. Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system.
Song B; Fan Y; He W; Zhu D; Niu X; Wang D; Ou Z; Luo M; Sun X
Stem Cells Dev; 2015 May; 24(9):1053-65. PubMed ID: 25517294
[TBL] [Abstract][Full Text] [Related]
11. Long-term correction of hemophilia B using adenoviral delivery of CRISPR/Cas9.
Stephens CJ; Lauron EJ; Kashentseva E; Lu ZH; Yokoyama WM; Curiel DT
J Control Release; 2019 Mar; 298():128-141. PubMed ID: 30771412
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse.
Guan Y; Ma Y; Li Q; Sun Z; Ma L; Wu L; Wang L; Zeng L; Shao Y; Chen Y; Ma N; Lu W; Hu K; Han H; Yu Y; Huang Y; Liu M; Li D
EMBO Mol Med; 2016 May; 8(5):477-88. PubMed ID: 26964564
[TBL] [Abstract][Full Text] [Related]
13. Naïve Induced Pluripotent Stem Cells Generated From β-Thalassemia Fibroblasts Allow Efficient Gene Correction With CRISPR/Cas9.
Yang Y; Zhang X; Yi L; Hou Z; Chen J; Kou X; Zhao Y; Wang H; Sun XF; Jiang C; Wang Y; Gao S
Stem Cells Transl Med; 2016 Jan; 5(1):8-19. PubMed ID: 26676643
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice.
Ohmori T; Nagao Y; Mizukami H; Sakata A; Muramatsu SI; Ozawa K; Tominaga SI; Hanazono Y; Nishimura S; Nureki O; Sakata Y
Sci Rep; 2017 Jun; 7(1):4159. PubMed ID: 28646206
[TBL] [Abstract][Full Text] [Related]
15. Targeted gene therapy in human-induced pluripotent stem cells from a patient with primary hyperoxaluria type 1 using CRISPR/Cas9 technology.
Estève J; Blouin JM; Lalanne M; Azzi-Martin L; Dubus P; Bidet A; Harambat J; Llanas B; Moranvillier I; Bedel A; Moreau-Gaudry F; Richard E
Biochem Biophys Res Commun; 2019 Oct; 517(4):677-683. PubMed ID: 31402115
[TBL] [Abstract][Full Text] [Related]
16. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
Doetschman T; Georgieva T
Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
[TBL] [Abstract][Full Text] [Related]
17. AAV mediated genome engineering with a bypass coagulation factor alleviates the bleeding phenotype in a murine model of hemophilia B.
Sarangi P; Kumar N; Sambasivan R; Ramalingam S; Amit S; Chandra D; Jayandharan GR
Thromb Res; 2024 Jun; 238():151-160. PubMed ID: 38718473
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
[TBL] [Abstract][Full Text] [Related]
19. Universal Correction of Blood Coagulation Factor VIII in Patient-Derived Induced Pluripotent Stem Cells Using CRISPR/Cas9.
Park CY; Sung JJ; Cho SR; Kim J; Kim DW
Stem Cell Reports; 2019 Jun; 12(6):1242-1249. PubMed ID: 31105049
[TBL] [Abstract][Full Text] [Related]
20. Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs.
Sung JJ; Park CY; Leem JW; Cho MS; Kim DW
Exp Mol Med; 2019 Apr; 51(4):1-9. PubMed ID: 30996250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
